On May 6, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education, reported that it will host the 20th Annual International Lung Cancer Congress from July 25 to 27 at the Huntington Regency Huntington Beach in California (Press release, Physicians’ Education Resource, MAY 6, 2019, View Source [SID1234535774]). The program will be chaired by Dr. David R. Gandara, professor of medicine in the division of hematology/oncology at the University of California (UC) at Davis School of Medicine and the director of the thoracic oncology program and senior adviser to the director at UC Davis Comprehensive Cancer Center, and Dr. Roy S. Herbst, Ensign professor of medicine (medical oncology), professor of pharmacology, chief of medical oncology and associate director for translational research at Yale Cancer Center, Yale School of Medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to celebrate 2 decades of educational excellence with this year’s upcoming International Lung Cancer Congress," said Phil Talamo, president of PER. "Now in its 20th year, the congress has become one of the most comprehensive and detailed educational lung cancer meetings in the world, with national and international faculty sharing perspectives on evolving data, discussing new patient management strategies, and reflecting on the evidence that drives the future treatment of lung cancer."
The 20th Annual International Lung Cancer Congress is a three-day program for surgical, medical and radiation oncologists interested in the treatment of patients with lung cancer. During this meeting, leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery and radiation oncology in the clinic through a series of cutting-edge lectures, panel discussions, multidisciplinary tumor boards and interactive Q&A sessions. Attendees who participate will have the opportunity to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.